ORHB - InvestorNewsBreaks - HippoFi Inc. (ORHB) Announces Launch of PURmarrow 360 Strategic Partnership for Near-Term Commercialization of New Technology
HippoFi (OTC: ORHB) is a leading health care technology company and authority in spinal biologics, focused on the development and distribution of innovative biotech products. The company today announced that, over the last six months, while under a confidential letter of intent (“LOI”) in a strategic partnership, it has designed and formulated a strategic launch of the PURmarrow 360 bone marrow aspirate (“BMA”) device throughout the United States. The product is a natural extension to HippoFi’s robust product line, allowing surgeons to selectively capture highly desired cells from a patient’s own BMA during surgery. The rich marrow enhances the effectiveness of PUR’s products by combining stem cells, growth factors and proteins, helping to supercharge bone growth in spine surgeries and improve patient healing. “As a market leader in innovation, we believe PURmarrow 360 is in the patient’s best interest, as the purity and genetic makeup of their own living cells is unmatched,” said CJ Wiggins, executive chairman and CEO of HippoFi. “PURmarrow 360 is simple to use, without requiring centrifugation, making it easy for spine surgeons to incorporate in every spine surgery.”
In addition, the company announced its entry into the final phase of negotiations for definitive agreements as part of the confidential LOI with a highly respected industry leader. HippoFi plans to soon announce the intended long-term strategic relationship, which will leverage the extensive expertise of both companies to create a breakthrough biomaterial that has already shown promise to be a game-changing solution for bone growth. “The companies will work together with the intent of near-term product commercialization to bring this new technology to health care providers and help improve patient’s functional outcomes,” Wiggins said of the collaboration.
To view the full press releases, visit https://ibn.fm/JSZYm and https://ibn.fm/LuB6E
About HippoFi Inc.
HippoFi delivers its cutting-edge health care innovations and propriety technologies through an extensive sales channel network, while implementing first-to-market solutions in the multibillion-dollar biotech, fintech and artificial intelligence (“AI”) markets. HippoFi comprises three segments: regenerative therapeutics, digital payments and AI, and utilizes the same customer channels to commercialize solutions, drive revenue and improve patient outcomes. HippoFi is publicly traded under the symbol ORHB and is headquartered in Irvine, California, USA. For more information, visit www.HippoFi.com and www.PURbiologics.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.